Teva Pharmaceuticals, Inc.
1090 Horsham Road
P.O. Box 1090
About Teva Pharmaceuticals, Inc.
TEVA Pharmaceuticals USA is the nation’s leading generic manufacturer, marketing the broadest product line in the U.S. with over 300 products. The company leads the industry in the number of new and total retail prescriptions in the U.S. Teva Pharmaceuticals USA employs approximately 1,200 people.
We believe that our quality people and the quality products that we market enhance the quality of life of patients and consumers throughout the world. Our achievements are possible due to the diligent efforts and complete dedication of these employees and our employees worldwide.
Part of what makes us successful is that as a company, we constantly analyze where we are today and where we need to be tomorrow. Teva USA's management philosophy is to develop leaders and their associates so that they may achieve professional and career success in the pharmaceutical business.
It is in this spirit that we provide our employees with many training and development opportunities necessary to cultivate and improve their skills, enhancing their career potential and growth. Teva USA views continuing education and development as the means to acquire the tools and techniques necessary to keep its employees and the organization in the forefront of leadership and good business practice.
Teva USA's future as the leader in the generic pharmaceutical industry hinges on both our individual and collective abilities. For these reasons, we rely on our diversity, creative solutions, teamwork and commitment to quality and customer service, which have built a tradition of customer satisfaction, value and profitability.
At Teva Pharmaceuticals USA, in addition to hard work, we also believe in having fun. We reinforce this belief through the events and activities that we sponsor. Company activities include an Easter Egg Hunt, a well-attended company picnic, and an annual Halloween pumpkin-carving contest. We also have an Activities Committee that organizes trips to local sporting events, short day trips, and theatre events. For the sports-minded, we have clubs to join such as running clubs and ski clubs. There's at least one activity or club to suit each and every employee!
As an organization, Teva is active in the community, involved in everything from sponsoring local theatre groups, sports teams and school programs, to donating medicines for humanitarian relief work around the globe.
Teva USA has an individual spirit of giving. Throughout the year employees participate in a variety of community enrichment drives. For example, the American Red Cross is welcomed here for organized Blood Drives. Employees also make contributions to various on-site programs such as food and clothing drives and children's gift-giving programs.
118 articles with Teva Pharmaceuticals, Inc.
Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar
If approved, CT-P10, a proposed biosimilar to Rituxan® (rituximab), will be the first rituximab biosimilar to be approved in the United States.
Sector Generates Significant Year-to-Date Leasing Volume – with More to Come
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets
Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceutical.
Teva Pharmaceuticals Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
U.S. District Judge in Philadelphia came down on the side of the Federal Trade Commission (FTC) in an anti-trust lawsuit filed in 2014 against AbbVie and its partner Besins Healthcare. They are ordered to pay $448 million.
As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
Teva is committed to providing access to affordable medicine around the world
Teva has a new headache. As the company pushes forward with its cost-cutting strategies, the company reported it is scrapping its chronic cluster headache program with fremanezumab.
Teva Pharmaceutical is in the midst of a $3 billion cost-cutting plan that includes cutting jobs worldwide. New Jersey has approved a plan that would save 1,000 jobs in New Jersey and relocate the company’s U.S. headquarters to Parsippany.
Allergan has gone to great lengths to defend the patents for its blockbuster dry-eye drug Restasis and it looks like the company will have to head back to court again.
5/18/2018Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data from the Phase III HALO study...
Shares of Perrigo have yet to rebound following the company’s weekend announcement that it expects the U.S. Food and Drug Administration to issue a Complete Response Letter for its generic version of Teva’s ProAir asthma inhaler.
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.